Ceptur Therapeutics
Signal active
Organization
Contact Information
Overview
Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS).
About
Industries
Biotechnology, Medical, Therapeutics
Founded
2008
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Ceptur Therapeutics headquartered in United States, North America, operates in the Biotechnology, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $1.9B in funding across 24 round(s). With a team of 11-50 employees, Ceptur Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Ceptur Therapeutics, raised $75.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
8
Lead Investors
0
Total Funding Amount
$81.2M
Details
1
Ceptur Therapeutics has raised a total of $81.2M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Early Stage Venture | 75.0M |
Investors
Ceptur Therapeutics is funded by 11 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Ceptur Therapeutics | - | FUNDING ROUND - Ceptur Therapeutics | 75.0M |
| Qiming Venture Partners | - | FUNDING ROUND - Qiming Venture Partners | 75.0M |
| Ceptur Therapeutics | - | FUNDING ROUND - Ceptur Therapeutics | 75.0M |
| Bristol-Myers Squibb | - | FUNDING ROUND - Bristol-Myers Squibb | 75.0M |
Recent Activity
There is no recent news or activity for this profile.